Last reviewed · How we verify
Lactobacillus reuteri 17938
At a glance
| Generic name | Lactobacillus reuteri 17938 |
|---|---|
| Sponsor | Tulane University School of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- All
- Fever
- Diarrhea
- Wheezing
- Vomiting
- Irritability
- Rash
- Pruritis
Key clinical trials
- The Efficacy of Preoperative Oral Administration of Lactobacillus Reuteri Combined With Preoperative Neoadjuvant/Conversion Immunotherapy in Patients With Primary Resectable Liver Cancer (NA)
- The Effects of Probiotic Supplementation on State and Trait Stress, Anxiety, and Depression Symptoms in Stressed Adults (NA)
- Role of Probiotic Use in Outcomes of Premature Birth (NA)
- Prevalence of FGIDs and Probiotics Study (NA)
- Lactobacillus Reuteri Strain Combination in Children Treated With PPI (NA)
- Prophylactic Probiotics to Extremely Low Birth Weight Prematures (PHASE2)
- Effects of Probiotic Oral Intake on Plasma Chlordecone (Kepone) Concentrations in Individuals Environmentally Exposed to Pesticide in Martinique. (NA)
- Lactobacillus Reuteri Strains for Gingivitis Reduction (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus reuteri 17938 CI brief — competitive landscape report
- Lactobacillus reuteri 17938 updates RSS · CI watch RSS
- Tulane University School of Medicine portfolio CI